Last reviewed · How we verify
Cell-culture based influenza vaccines
Cell-culture based influenza vaccines, marketed by the Henry M. Jackson Foundation for the Advancement of Military Medicine, hold a niche position in the influenza vaccine market. A key strength is the stability of the product's composition, protected by a key patent expiring in 2028. The primary risk is the lack of significant revenue data, which may limit investment and market expansion opportunities.
At a glance
| Generic name | Cell-culture based influenza vaccines |
|---|---|
| Sponsor | Henry M. Jackson Foundation for the Advancement of Military Medicine |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations (PHASE4)
- Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP (PHASE4)
- A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PHASE4)
- H3N2 M2SR in Pediatric Population (PHASE1)
- Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults (PHASE1)
- Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix (PHASE1)
- Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: